Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Waldenström Macroglobulinemia
Related studies linked through entity extraction aliases.
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
- Status
- COMPLETED
- Phase
- NA
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Status
- TERMINATED
- Phase
- PHASE1
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2